A myostatin and activin decoy receptor enhances bone formation in mice

Bone

Volumn 60, Issue , 2014, Pages 162-171

  Bialek, P ^a   Parkington, J ^a,b   Li, X ^a,c   Gavin, D ^a   Wallace, C ^a   Zhang, J ^a,b   Root, A ^a   Yan, G ^a   Warner, L ^a,d   Seeherman, H J ^a,e   Yaworsky, P J ^a  

^a PFIZER INC   (United States)

^b NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^c PERKINELMER INC   (United States)

^d AVI BIOPHARMA INC   (United States)

^e BIOVENTUS LLC   (United States)

Author keywords

ActRIIB Fc; BMP3; Bone histomorphometry; Mechanical testing; Myostatin; Rodent

Indexed keywords

ACTIVIN RECEPTOR 2; ACTIVIN RECEPTOR 2B; MYOSTATIN; NEUTRALIZING ANTIBODY; OSTEOGENIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BONE MASS; CONTROLLED STUDY; FEMALE; FEMUR; LIGAND BINDING; LUMBAR VERTEBRA; MICRO-COMPUTED TOMOGRAPHY; MOUSE; MUSCLE MASS; NONHUMAN; OSSIFICATION; PROTEIN FUNCTION; RECEPTOR BINDING; TRABECULAR BONE;

ACTRIIB-FC; BMP3; BONE HISTOMORPHOMETRY; MECHANICAL TESTING; MYOSTATIN; RODENT;

ACTIVIN RECEPTORS; ANABOLIC AGENTS; ANIMALS; ANTIBODIES, MONOCLONAL; BODY WEIGHT; BONE AND BONES; BONE MORPHOGENETIC PROTEIN 3; FEMALE; MICE; MICE, INBRED C57BL; MUSCLES; MYOSTATIN; ORGAN SIZE; OSTEOGENESIS; PARATHYROID HORMONE; RECEPTORS, FC; X-RAY MICROTOMOGRAPHY;

EID: 84891363681     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2013.12.002     Document Type: Article

References (68)

1. McPherron A.C., Lawler A.M., Lee S.J. Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member. Nature 1997, 387(6628):83-90.
2. Mateescu R.G., Thonney M.L. Gene expression in sexually dimorphic muscles in sheep. J Anim Sci 2002, 80(7):1879-1887.
3. McPherron A.C., Lee S.J. Double muscling in cattle due to mutations in the myostatin gene. Proc Natl Acad Sci U S A 1997, 94(23):12457-12461.
4. Smith T.P., Lopez-Corrales N.L., Kappes S.M., Sonstegard T.S. Myostatin maps to the interval containing the bovine mh locus. Mamm Genome 1997, 8(10):742-744.
5. Kambadur R., Sharma M., Smith T.P., Bass J.J. Mutations in myostatin (GDF8) in double-muscled Belgian Blue and Piedmontese cattle. Genome Res 1997, 7(9):910-916.
6. Xu C., Wu G., Zohar Y., Du S.J. Analysis of myostatin gene structure, expression and function in zebrafish. J Exp Biol 2003, 206(Pt 22):4067-4079.
7. Acosta J., Caprio Y., Borroto I., Gonzalez O., Estrada M.P. Myostatin gene silenced by RNAi show a zebrafish giant phenotype. J Biotechnol 2005, 119(4):324-331.
8. Shelton G.D., Engvall E. Gross muscle hypertrophy in whippet dogs is caused by a mutation in the myostatin gene. Neuromuscul Disord 2007, 17(9-10):721-722.
9. Mosher D.S., Quignon P., Bustamante C.D., Sutter N.B., Mellersh C.S., Parker H.G., et al. A mutation in the myostatin gene increases muscle mass and enhances racing performance in heterozygote dogs. PLoS Genet 2007, 3(5):e79.
10. Schuelke M., Wagner K.R., Stolz L.E., Hubner C., Riebel T., Komen W., et al. Myostatin mutation associated with gross muscle hypertrophy in a child. N Engl J Med 2004, 350(26):2682-2688. [see comment].
11. Bradley L., Yaworsky P.J., Walsh F.S. Myostatin as a therapeutic target for musculoskeletal disease. Cell Mol Life Sci 2008, 65(14):2119-2124.
12. Attie K.M., Borgstein N.G., Yang Y., Condon C.H., Wilson D.M., Pearsall A.E., et al. A single ascending-dose study of muscle regulator ACE-031 in healthy volunteers. Muscle Nerve 2012, 47(3):416-423.
13. Hamrick M.W. A role for myokines in muscle-bone interactions. Exerc Sport Sci Rev 2011, 39(1):43-47.
14. Havekes B., Sauerwein H.P. Adipocyte-myocyte crosstalk in skeletal muscle insulin resistance; is there a role for thyroid hormone?. Curr Opin Clin Nutr Metab Care 2010, 13(6):641-646.
15. Feldman B.J., Streeper R.S., Farese R.V., Yamamoto K.R. Myostatin modulates adipogenesis to generate adipocytes with favorable metabolic effects. Proc Natl Acad Sci U S A 2006, 103(42):15675-15680.
16. Sharma M., Kambadur R., Matthews K.G., Somers W.G., Devlin G.P., Conaglen J.V., et al. Myostatin, a transforming growth factor-beta superfamily member, is expressed in heart muscle and is upregulated in cardiomyocytes after infarct. J Cell Physiol 1999, 180(1):1-9.
17. Hirai S., Matsumoto H., Hino N., Kawachi H., Matsui T., Yano H. Myostatin inhibits differentiation of bovine preadipocyte. Domest Anim Endocrinol 2007, 32(1):1-14.
18. Karsenty G., Ferron M. The contribution of bone to whole-organism physiology. Nature 2012, 481(7381):314-320.
19. Springer J., Adams V., Anker S.D. Myostatin: regulator of muscle wasting in heart failure and treatment target for cardiac cachexia. Circulation 2010, 121(3):354-356.
20. Hamrick M.W. Increased bone mineral density in the femora of GDF8 knockout mice. Anat Rec A: Discov Mol Cell Evol Biol 2003, 272(1):388-391.
21. Hamrick M.W., McPherron A.C., Lovejoy C.O. Bone mineral content and density in the humerus of adult myostatin-deficient mice. Calcif Tissue Int 2002, 71(1):63-68.
22. Hamrick M.W., McPherron A.C., Lovejoy C.O., Hudson J., et al. Femoral morphology and cross-sectional geometry of adult myostatin-deficient mice. Bone 2000, 27(3):343-349.
23. Hamrick M.W., Pennington C., Byron C.D. Bone architecture and disc degeneration in he lumbar spine of mice lacking GDF-8 (myostatin). J Orthop Res 2003, 21(6):1025-1032.
24. Nicholson E.K., Stock S.R., Hamrick M.W., Ravosa M.J. Biomineralization and adaptive plasticity of the temporomandibular joint in myostatin knockout mice. Arch Oral Biol 2006, 51(1):37-49.
25. Cho T.-J., Gerstenfeld L.C., Einhorn T.A. Differential temporal expression of members of the transforming growth factor beta superfamily during murine fracture healing. J Bone Miner Res 2002, 17(3):513-520.
26. Kellum E., Starr H., Arounleut P., Immel D., Fulzele S., Wenger K., et al. Myostatin (GDF-8) deficiency increases fracture callus size, Sox-5 expression, and callus bone volume. Bone 2009, 44(1):17-23.
27. Amling M., Takeda S., Karsenty G. A neuro (endo)crine regulation of bone remodeling. Bioessays 2000, 22(11):970-975.
28. Souza T.A., Guo Y., Sava P., Zhang J., Hill J.J., et al. Proteomic identification and functional validation of activins and bone morphogenetic protein 11 as candidate novel muscle mass regulators. Mol Endocrinol 2008, 22(12):2689-2702.
29. de Caestecker M. The transforming growth factor-beta superfamily of receptors. Cytokine Growth Factor Rev 2004, 15(1):1-11.
30. Rebbapragada A., Benchabane H., Wrana J.L., Celeste A.J., Attisano L. Myostatin signals through a transforming growth factor beta-like signaling pathway to block adipogenesis. Mol Cell Biol 2003, 23(20):7230-7242.
31. Pearsall R.S., Canalis E., Cornwall-Brady M., Underwood K.W., Haigis B., Ucran J., et al. A soluble activin type IIA receptor induces bone formation and improves skeletal integrity. Proc Natl Acad Sci U S A 2008, 105(19):7082-7087.
32. Lee S.J., Reed L.A., Davies M.V., Girgenrath S., Goad M.E., Tomkinson K.N., et al. Regulation of muscle growth by multiple ligands signaling through activin type II receptors. Proc Natl Acad Sci U S A 2005, 102(50):18117-18122.
33. Shuto T., Sarkar G., Bronk J.T., Matsui N., Bolander M.E. Osteoblasts express types I and II activin receptors during early intramembranous and endochondral bone formation. J Bone Miner Res 1997, 12(3):403-411.
34. Hamrick M.W., Shi X., Zhang W., Pennington C., Thakore H., Haque M., et al. Loss of myostatin (GDF8) function increases osteogenic differentiation of bone marrow-derived mesenchymal stem cells but the osteogenic effect is ablated with unloading. Bone 2007, 40(6):1544-1553.
35. Chen G., Deng C., Li Y.P. TGF-beta and BMP signaling in osteoblast differentiation and bone formation. Int J Biol Sci 2012, 8(2):272-288.
36. Karsenty G. Central control of bone formation. Ann Endocrinol (Paris) 2002, 63(2 Pt 1):145-153.
37. Daluiski A., Engstrand T., Bahamonde M.E., Gamer L.W., Agius E., Stevenson S.L., et al. Bone morphogenetic protein-3 is a negative regulator of bone density. Nat Genet 2001, 27(1):84-88.
38. Gamer L.W., Cox K., Carlo J.M., Rosen V. Overexpression of BMP3 in the developing skeleton alters endochondral bone formation resulting in spontaneous rib fractures. Dev Dyn 2009, 238(9):2374-2381.
39. Hill J.J., Davies M.V., Pearsall A.A., Wang J.H., Hewick R.M., Wolfman N.M., et al. The myostatin propeptide and the follistatin-related gene are inhibitory binding proteins of myostatin in normal serum. J Biol Chem 2002, 277(43):40735-40741.
40. Bogdanovich S., Krag T.O., Barton E.R., Morris L.D., Whittemore L.A., Ahima R.S, et al. Functional improvement of dystrophic muscle by myostatin blockade. Nature 2002, 420(6914):418-421.
41. Glatt V., Canalis E., Stadmeyer L., Bouxsein M.L. Age-related changes in trabecular architecture differ in female and male C57BL/6J mice. J Bone Miner Res 2007, 22(8):1197-1207.
42. Seeherman H.J., Bouxsein M., Kim H., Li R., Li X.J., Aiolova M., et al. Recombinant human bone morphogenetic protein-2 delivered in an injectable calcium phosphate paste accelerates osteotomy-site healing in a nonhuman primate model. J Bone Joint Surg Am 2004, 86-A(9):1961-1972.
43. Allen D.L., Banstra E.R., Harrison B.C., Thorng S., Stodieck L.S., Kostenuik P.J., et al. Effects of spaceflight on murine skeletal muscle gene expression. J Appl Physiol 2009, 106(2):582-595.
44. Lalani R., Bhasin S., Byhower F., Tarnuzzer R., Grant M., Shen R., et al. Myostatin and insulin-like growth factor-I and -II expression in the muscle of rats exposed to the microgravity environment of the NeuroLab space shuttle flight. J Endocrinol 2000, 167(3):417-428.
45. McMahon C.D., Popovic L., Oldman J.M., Jeanplong F., Smith H.K., Kambadur R., et al. Myostatin-deficient mice lose more skeletal muscle mass than wild-type controls during hindlimb suspension. Am J Physiol Endocrinol Metab 2003, 285(1):E82-E87.
46. Kawada S., Tachi C., Ishii N. Content and localization of myostatin in mouse skeletal muscles during aging, mechanical unloading and reloading. J Muscle Res Cell Motil 2001, 22(8):627-633.
47. Nguyen J., Tang S.Y., Nguyen D., Alliston T., et al. Load regulates bone formation and sclerostin expression through a TGFbeta-dependent mechanism. PLoS One 2013, 8(1):e53813.
48. Wolfman N.M., McPherron A.C., Pappano W.N., Davies M.V., Song K., Tomkinson K.N., et al. Activation of latent myostatin by the BMP-1/tolloid family of metalloproteinases. Proc Natl Acad Sci U S A 2003, 100(26):15842-15846.
49. Townson S.A., Martinez-Hackert E., Greppi C., Lowden P., Sako D., Liu J., et al. Specificity and structure of a high affinity activin receptor-like kinase 1 (ALK1) signaling complex. J Biol Chem 2012, 287(33):27313-27325.
50. Sako D., Grinberg A.V., Liu J., Davies M.V., Castonguay R., Maniatis S., et al. Characterization of the ligand binding functionality of the extracellular domain of activin receptor type IIb. J Biol Chem 2010, 285(27):21037-21048.
51. Fajardo R.J., Manoharan R.K., Pearsall R.S., Davies M.V., Marvell T., Monnell T.E., et al. Treatment with a soluble receptor for activin improves bone mass and structure in the axial and appendicular skeleton of female cynomolgus macaques (Macaca fascicularis). Bone 2010, 46(1):64-71.
52. Lotinun S., Pearsall R.S., Davies M.V., Marvell T.H., Monnell T.E., Ucran J., et al. A soluble activin receptor Type IIA fusion protein (ACE-011) increases bone mass via a dual anabolic-antiresorptive effect in Cynomolgus monkeys. Bone 2010, 46(4):1082-1088.
53. Ogawa Y., Schmidt D.K., Nathan R.M., Armstrong R.M., Miller K.L., Sawamura S.J., et al. Bovine bone activin enhances bone morphogenetic protein-induced ectopic bone formation. J Biol Chem 1992, 267(20):14233-14237.
54. Fuller K., Bayley K.E., Chambers T.J. Activin A is an essential cofactor for osteoclast induction. Biochem Biophys Res Commun 2000, 268(1):2-7.
55. Sakai R., Eto Y., Ohtsuka M., Hirafuji M., Shinoda H. Activin enhances osteoclast-like cell formation in vitro. Biochem Biophys Res Commun 1993, 195(1):39-46.
56. Sakai R., Miwa K., Eto Y. Local administration of activin promotes fracture healing in the rat fibula fracture model. Bone 1999, 25(2):191-196.
57. Sakai R., Fujita S., Horie T., Ohyama T., Miwa K., Maki T., et al. Activin increases bone mass and mechanical strength of lumbar vertebrae in aged ovariectomized rats. Bone 2000, 27(1):91-96.
58. Perrien D.S., Akel N.S., Edwards P.K., Carver A.A., Bendre M.S., Swain F.L., et al. Inhibin A is an endocrine stimulator of bone mass and strength. Endocrinology 2007, 148(4):1654-1665.
59. Esbrit P., Alcaraz M.J. Current perspectives on parathyroid hormone (PTH) and PTH-related protein (PTHrP) as bone anabolic therapies. Biochem Pharmacol 2013, 85(10):1417-1423.
60. Chiu C.S., Peekhaus N., Weber H., Adamski S., Murray E.M., Zhang H.Z., et al. Increased muscle force production and bone mineral density in ActRIIB-Fc-treated mature rodents. J Gerontol A Biol Sci Med Sci 2013, 68(10):1181-1192.
61. Papapoulos S.E. Targeting sclerostin as potential treatment of osteoporosis. Ann Rheum Dis 2011, 70(Suppl. 1):i119-i122.
62. Rhee Y., Lee E.Y., Lezcano V., Ronda A.C., Condon K.W., Allen M.R., et al. Resorption controls bone anabolism driven by parathyroid hormone (PTH) receptor signaling in osteocytes. J Biol Chem 2013, 288(41):29809-29820.
63. Badhi D., Jang G., Stouch B., Fang L., Posvar E. Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J Bone Miner Res 2011, 26(1):19-26.
64. Fernandez-Garcia D., Munoz-Torres M., Mezquita-Raya P., de la Higuera M., Alonso G., et al. Effects of raloxifene therapy on circulating osteoprotegerin and RANK ligand levels in post-menopausal osteoporosis. J Endocrinol Invest 2008, 31(5):416-421.
65. Cummings S.R., San Martin J., McClung M.R., Siris E.S., Eastell R., Reid I.R., et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009, 361(8):756-765.
66. Tsai J.N., Uihlein A.V., Lee H., Kumbhani R., Siwila-Sackman E., McKay E.A., et al. Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial. Lancet 2013, 382(9886):50-56.
67. Bonnick S., De Villiers T., Odio A., Palacious S., Chapurlat R., Dasilva C., et al. Effects of odanacatib on BMD and safety in the treatment of osteoporosis in postmenopausal women previously treated with alendronate: a randomized placebo-controlled trial. J Clin Endocrinol Metab 2013, (12):4727-4735.
68. Liu J., Xu K., Wen G., Guo H., Li S., Wu X., et al. Comparison of the effects of genistein and zoledronic acid on the bone loss in OPG-deficient mice. Bone 2008, 42(5):950-959.